These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 14747959)
41. The importance of age over radioiodine avidity as a prognostic factor in differentiated thyroid carcinoma with distant metastases. Mihailovic J; Stefanovic L; Malesevic M; Markoski B Thyroid; 2009 Mar; 19(3):227-32. PubMed ID: 19265493 [TBL] [Abstract][Full Text] [Related]
42. Multifactorial analysis of survival and recurrences in differentiated thyroid cancer. Comparative evaluation of usefulness of AGES, MACIS, and risk group scores in Mexican population. Rodríguez-Cuevas S; Labastida-Almendaro S; Cortés-Arroyo H; López-Garza J; Barroso-Bravo S J Exp Clin Cancer Res; 2002 Mar; 21(1):79-86. PubMed ID: 12071534 [TBL] [Abstract][Full Text] [Related]
43. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer. de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550 [TBL] [Abstract][Full Text] [Related]
44. Radiotherapy for primary thyroid cancer as a risk factor for second primary cancers. Chuang SC; Hashibe M; Yu GP; Le AD; Cao W; Hurwitz EL; Rao JY; Neugut AI; Zhang ZF Cancer Lett; 2006 Jul; 238(1):42-52. PubMed ID: 16039041 [TBL] [Abstract][Full Text] [Related]
45. Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Hindié E; Mellière D; Lange F; Hallaj I; de Labriolle-Vaylet C; Jeanguillaume C; Lange J; Perlemuter L; Askienazy S Eur J Nucl Med Mol Imaging; 2003 Jul; 30(7):974-81. PubMed ID: 12734689 [TBL] [Abstract][Full Text] [Related]
46. Trends in treatment and long-term survival of thyroid cancer in southeastern Netherlands, 1960-1992. Kuijpens JL; Hansen B; Hamming JF; Ribot JG; Haak HR; Coebergh JW Eur J Cancer; 1998 Jul; 34(8):1235-41. PubMed ID: 9849486 [TBL] [Abstract][Full Text] [Related]
47. Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. Song HJ; Qiu ZL; Shen CT; Wei WJ; Luo QY Eur J Endocrinol; 2015 Sep; 173(3):399-408. PubMed ID: 26104753 [TBL] [Abstract][Full Text] [Related]
48. Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patients. Verburg FA; Mäder U; Reiners C; Hänscheid H J Clin Endocrinol Metab; 2014 Dec; 99(12):4487-96. PubMed ID: 25259907 [TBL] [Abstract][Full Text] [Related]
49. Hürthle cell carcinoma: a clinicopathological study of thirteen cases. Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925 [TBL] [Abstract][Full Text] [Related]
50. Risk of thyroid cancer in first-degree relatives of patients with non-medullary thyroid cancer by histology type and age at diagnosis: a joint study from five Nordic countries. Fallah M; Pukkala E; Tryggvadottir L; Olsen JH; Tretli S; Sundquist K; Hemminki K J Med Genet; 2013 Jun; 50(6):373-82. PubMed ID: 23585692 [TBL] [Abstract][Full Text] [Related]
51. Improving postoperative recurrence rates for carcinoma of the thyroid gland. McHenry C; Jarosz H; Lawrence AM; Paloyan E Surg Gynecol Obstet; 1989 Nov; 169(5):429-34. PubMed ID: 2814754 [TBL] [Abstract][Full Text] [Related]
52. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts. Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541 [TBL] [Abstract][Full Text] [Related]
53. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. Marees T; Moll AC; Imhof SM; de Boer MR; Ringens PJ; van Leeuwen FE J Natl Cancer Inst; 2008 Dec; 100(24):1771-9. PubMed ID: 19066271 [TBL] [Abstract][Full Text] [Related]
54. Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma. Kita T; Yokoyama K; Higuchi T; Kinuya S; Taki J; Nakajima K; Michigishi T; Tonami N Ann Nucl Med; 2004 Jun; 18(4):345-9. PubMed ID: 15359929 [TBL] [Abstract][Full Text] [Related]
55. Second primary malignancies in thyroid cancer patients. Rubino C; de Vathaire F; Dottorini ME; Hall P; Schvartz C; Couette JE; Dondon MG; Abbas MT; Langlois C; Schlumberger M Br J Cancer; 2003 Nov; 89(9):1638-44. PubMed ID: 14583762 [TBL] [Abstract][Full Text] [Related]
56. Second primary tumors following thyroid cancer. A Swedish record-linkage study. Hall P; Holm LE; Lundell G Acta Oncol; 1990; 29(7):869-73. PubMed ID: 2261200 [TBL] [Abstract][Full Text] [Related]
57. 131I treatment for thyroid cancer and risk of developing primary hyperparathyroidism: a cohort study. Lin CM; Doyle P; Tsan YT; Lee CH; Wang JD; Chen PC; Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):253-9. PubMed ID: 23982456 [TBL] [Abstract][Full Text] [Related]
58. To the editor: Long-term follow-up of patients with metastatic differentiated thyroid carcinoma. Bertagna F; Giubbini R World J Surg; 2010 Aug; 34(8):1988-9; author reply 1990. PubMed ID: 20151122 [No Abstract] [Full Text] [Related]
59. Increased rate of dicentric chromosomes in French Polynesian thyroid cancer patients? Pauwels EK Eur J Nucl Med Mol Imaging; 2006 Mar; 33(3):382; author reply 383. PubMed ID: 16292628 [No Abstract] [Full Text] [Related]
60. Multiple primary non-breast tumors in breast cancer survivors. Corso G; Veronesi P; Santomauro GI; Maisonneuve P; Morigi C; Peruzzotti G; Intra M; Sacchini V; Galimberti V J Cancer Res Clin Oncol; 2018 May; 144(5):979-986. PubMed ID: 29502170 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]